Pulmatrix (PULM) Accumulated Depreciation (2014 - 2024)
Pulmatrix (PULM) posted Accumulated Depreciation of $1.8 million for Q1 2024, up 3.4% sequentially from $1.7 million in Q4 2023, and down 35.43% YoY from $2.8 million in Q2 2023.
Pulmatrix (PULM) Accumulated Depreciation (2014 - 2024) Analysis & Trends
Pulmatrix has reported Accumulated Depreciation for 10 years, with the latest figure at $1.8 million in Q1 2024.
- Quarterly Accumulated Depreciation fell 35.43% year-over-year to $1.8 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $1.8 million (down 35.43% YoY) and the FY2023 annual result came in at $1.7 million, down 36.83% from the prior year.
- Accumulated Depreciation advanced to $1.8 million in Q1 2024 per PULM's latest filing, from $1.7 million in the prior quarter.
- Over five years, Accumulated Depreciation peaked at $2.8 million in Q2 2023 and troughed at $1.7 million in Q3 2023.
- A 5-year average of $2.4 million and a median of $2.7 million in 2021 frame the typical range for Accumulated Depreciation.
- The sharpest annual moves came in 2020 and 2023: Accumulated Depreciation advanced 8.58% in 2020, then slumped 38.29% in 2023.
- Over 5 years, Accumulated Depreciation stood at $2.5 million in 2020, then grew by 6.41% to $2.6 million in 2021, then climbed by 4.09% to $2.7 million in 2022, then tumbled by 36.83% to $1.7 million in 2023, then grew by 3.4% to $1.8 million in 2024.
- According to Business Quant data, Accumulated Depreciation over the past three periods registered $1.8 million, $1.7 million, and $1.7 million for Q1 2024, Q4 2023, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 1.80 Mn |
| Dec 31, 2023 | 1.74 Mn |
| Sep 30, 2023 | 1.70 Mn |
| Jun 30, 2023 | 2.80 Mn |
| Mar 31, 2023 | 2.78 Mn |
| Dec 31, 2022 | 2.75 Mn |
| Sep 30, 2022 | 2.75 Mn |
| Jun 30, 2022 | 2.71 Mn |
| Mar 31, 2022 | 2.67 Mn |
| Dec 31, 2021 | 2.64 Mn |
| Mar 31, 2021 | 2.53 Mn |
| Dec 31, 2020 | 2.48 Mn |
| Dec 31, 2019 | 2.29 Mn |
| Dec 31, 2017 | 2.87 Mn |
| Dec 31, 2016 | 2.67 Mn |
| Dec 31, 2015 | 2.61 Mn |
| Dec 31, 2014 | 2.53 Mn |